Koagülasyon Kaskadı ve Antikoagülanlar

Authors

Elif Sıla Erim
https://orcid.org/0000-0002-7958-7654

Synopsis

This section covers the hemostasis mechanism, coagulation cascade, and anticoagulant therapies in detail. Hemostasis relies on a delicate balance between the vascular wall, platelets, coagulation factors, natural anticoagulants, and the fibrinolytic system. Following vascular injury, vasoconstriction, primary hemostasis (platelet adhesion, secretion, and aggregation), and secondary hemostasis (coagulation cascade) are triggered sequentially. Contrary to the traditional intrinsic/extrinsic division, the modern model consists of initiation, amplification, and propagation phases. The fibrin clot is stabilized by Factor XIII and broken down via plasmin during fibrinolysis. Primary and secondary hemostasis disorders are evaluated using tests such as bleeding time, PT, aPTT, along with clinical history. In cases of hereditary or acquired thrombophilia, anticoagulant drugs are used to prevent stroke and venous thromboembolism risks. While unfractionated heparin, low molecular weight heparins (LMWH), and fondaparinux are administered parenterally, vitamin K antagonists (warfarin) and novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) are administered orally. Warfarin requires regular INR monitoring due to its narrow therapeutic window and drug/food interactions, whereas novel oral anticoagulants stand out with quick onset, lack of routine laboratory monitoring, and low interaction profiles. Additionally, anticoagulant prophylaxis plays a crucial role in preventing micro-thrombotic processes in COVID-19 patients.

References

Hoffman M, Monroe DM; A cell-based model of hemostasis. Thromb Haemostas 2001 Jun;85(6):958-65.

Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis.2009; 20: 89-100.

Xiaohong Ruby Xu at all. Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Thrombosis Journal volume 14, Article number: 29 (2016)

MacFarlane RG.An enzyme cascade in the blood clotting mechanism and its function as a bio-chemical amplifier.Nature, 202 (1994).

Francisco Pérez-Gómez, Ramón Bover. The New Coagulation Cascade and Its Possible Influence on the Delicate Balance Between Thrombosis and Hemorrhage. Revista espanola de cardiologia. Vol. 60. Issue 12.pages 1217-1219 (December 2007)

Lord ST. Molecular mechanisms affecting fibrin structure and stability (Review).Arterioscler Thromb Vasc Biol 2011;31:494-9.

Tsurupa G, Mahid A, Veklich Y, Weisel JW, Med-ved L. Structure, Stability, and Interaction of Fi-brin αC-Domain Polymers. Biochemistry. 2011 Aug 24

Gebbink MF. Tissue-type plasminogen activator-mediated plasminogenactivation and contact activation, implications in and beyond haemostasis. J.Thromb Haemost. 2011; Suppl 1:174-8.

Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009;113: 2878-87.

Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood 2016; 128:104.

Lefkou E, Khamashta M, Hampson G, et al. Review: Lowmolecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus 2010;19:3-12

Kayaalp SO. Antitrombotik ilaçlar. In: Kayaalp SO ed.Rasyonel tedavi yönünden tıbbi farmakoloji. Dokuzuncu baskı.Ankara, Hacettepe Taş Kitapçılık Ltd Şti., 2000: 584-617.

Antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP Guidelines Chest 2012;141(Suppl):152S-84S.

The EINSTEIN Investigators. Oral rivaroxaban for symptomaticvenous thromboembolism. N Engl J Med 2010 Dec.23;363:2499-510.

The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.

Agnelli G, Buller HR, Cohen A, et al. AMPLIFY investigators.Oral apixaban for the treatment of acute venous thromboembolism..N Engl J Med 2013;369:799-808.

Hokusai-VTE investigators, Buller HR, Decousus H, et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.

Schulman S, Kearon C, Kakkar AK, et al. REMEDY trial investigators. RE–SONATE trial investigators. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18

Schulman S. Advantages and limitations of the new anticoagulants..J Intern Med 2014;275:1-11

Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamicsof the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53.

Heparin İlişkili Trombositopeni (Hit) Tanı Ve Tedavi Kılavuzu 2011, Türk Hematoloji Derneği

Robert S.Hillman, Kenneth A.Ault, Henry M.Rinder. Hematology in Clinical Practice, Fifth Edition 2010.

Edward Wing, Fred schiffman. Cecil Essentials of Medicine 10th Edition. March 2021.

Published

January 5, 2022

License

License